A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Status:
WITHDRAWN
Trial end date:
2024-11-05
Target enrollment:
Participant gender:
Summary
To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.